进入财报季，各个公司逐渐交出了2025年的业绩答卷。 2月26日，AI制药的两大头部玩家——薛定谔（Schrödinger）和“英伟达概念股”Recursion罕见地在同一天发布财报。

REC-994是Recursion立项最早的项目之一，一度也是进度最靠前的临床管线，并且在Ⅱ期研究中，展现出病灶缩小、功能改善的积极信号，但在后续的长期扩展研究中，这种疗效未能维持，转换剂量组也没有积极趋势。

Recursion Pharmaceuticals(纳斯达克股票代码:RXRX)于2026年2月25日公布了2025年第四季度及全年业绩,展示了其AI驱动药物发现平台的首次临床验证以及显著的财务纪律。该公司公布的业绩好于预期,2025年第四季度每股收益为-$0.21,超出预期的-$0.30,营收为$35.54百万,超出预期45%。该股在盘前交易中飙升11%至$3.92,反映出投资者对公司临床和运营 ...

Recursion Pharmaceuticals将于周三美股开盘前公布2025年第四季度及全年业绩,投资者密切关注这家AI驱动的生物科技公司能否将其庞大的数据平台转化为持续的收入增长和临床成功。 分析师预计该公司每股亏损30美分,营收为2450万美元,较第三季度每股亏损36美分、营收仅520万美元有大幅改善。营收近五倍的增长将成为Recursion商业模式的关键验证点,该模式依赖于与罗氏、拜耳和 ...

Recursion Pharmaceuticals leverages AI and machine learning to revolutionize drug discovery, reducing costs and accelerating development, positioning itself as a leader in tech-driven biopharma. The ...

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the AI stocks that will go to the moon. On February 18, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) came under pressure after regulatory ...

Kyiv, Ukraine and Salt Lake City, UT, April 09, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced ...

Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...

The market is viewing NVIDIA's decision to keep its 7.7 million share stake in Recursion while divesting from other AI holdings as a significant strategic move. This decision indicates NVIDIA's ...

SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with ...